Phase 1 Frontotemporal Dementia Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1Phase 2

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Frontotemporal DementiaFTDDementia, Frontotemporal+1 more

AviadoBio Ltd18 enrolled19 locationsNCT06064890

Recruiting

Phase 1Phase 2

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

Frontotemporal DementiaFTDFTD-GRN

Passage Bio, Inc.30 enrolled10 locationsNCT04747431

Recruiting

Phase 1Phase 2

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

DementiaAlzheimer DiseaseFrontotemporal Dementia

David Wilson102 enrolled1 locationNCT05374278